Improved survival with elevated BMI following immune checkpoint inhibition across various solid tumor cancer types.

ABSTRACT:

Introduction/background

Obesity is a well-known risk factor for various cancers, yet emerging research demonstrates its association with improved survival outcomes in cancer treatment, labeled as "the obesity paradox." Studies investigating the clinical benefits of obesity across various cancer types after immune checkpoint inhibition (ICI) are limited.

Methods

Data were queried from the TriNetX database to identify patients with solid tumor malignancies of various organ systems (pulmonary/intrathoracic, cutaneous, head and neck, gastrointestinal, breast, genitourinary) who received ICI between 2012 and 2024. Propensity score matching was used to match cohorts for demographics, medical comorbidities, and oncologic staging. Primary outcome was overall survival (OS) up to 5 ye

SUBMITTER: Mastrolonardo EV 

PROVIDER: S-EPMC11897419 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature